Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma
- PMID: 8379024
- DOI: 10.1016/0090-4295(93)90612-e
Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma
Abstract
From May 1985 to December 1990, 93 patients with the clinical diagnosis of metastatic renal cell carcinoma and their primary tumor in place were evaluated for cytoreductive surgery as preparation for systemic therapy with regimens based on interleukin-2. These patients had typical sites of metastatic disease and manifestations of paraneoplastic syndromes. Patients underwent removal of the primary tumor, as well as debulking when this could be performed safely. Thirty-two percent of patients (30/93) had a second surgical resection in addition to their nephrectomy, frequently because of the large size of the primary tumor and its invasion of adjacent structures. Thirteen percent of patients (12/93) experienced postoperative complications. There were no perioperative mortalities. Forty percent of patients (37/93) who underwent nephrectomy could not be treated with immunotherapy, usually because of progression of disease. A preoperative ECOG status greater than or equal to 2 was the only significant risk factor associated with failure to undergo immunotherapy (P = 0.043). The response rate to immunotherapy in the 56 patients receiving interleukin-2 was 27 percent (4 CR, 11 PR).
Similar articles
-
Interleukin-2 immunotherapy followed by resection of residual renal cell carcinoma.J Urol. 1991 May;145(5):938-41. doi: 10.1016/s0022-5347(17)38495-1. J Urol. 1991. PMID: 2016805
-
Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience.Semin Urol Oncol. 1996 Nov;14(4):230-6. Semin Urol Oncol. 1996. PMID: 8946623
-
Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells.J Urol. 1990 Sep;144(3):614-7; discussion 617-8. doi: 10.1016/s0022-5347(17)39537-x. J Urol. 1990. PMID: 2201792 Clinical Trial.
-
Interferons and interleukins in metastatic renal cell carcinoma.Urology. 1993 Jan;41(1 Suppl):67-72. doi: 10.1016/0090-4295(93)90199-k. Urology. 1993. PMID: 7678365 Review.
-
Cytoreductive nephrectomy in metastatic renal cancer.Curr Urol Rep. 2003 Feb;4(1):36-40. doi: 10.1007/s11934-003-0055-6. Curr Urol Rep. 2003. PMID: 12537937 Review.
Cited by
-
Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach.Front Oncol. 2017 May 31;7:107. doi: 10.3389/fonc.2017.00107. eCollection 2017. Front Oncol. 2017. PMID: 28620578 Free PMC article. Review.
-
Surgical management of metastatic renal cell carcinoma in the era of targeted therapies.World J Urol. 2014 Jun;32(3):615-22. doi: 10.1007/s00345-014-1286-5. Epub 2014 Apr 4. World J Urol. 2014. PMID: 24700309 Review.
-
Cytoreductive nephrectomy for metastatic renal cell carcinoma: a review of the historical literature and its role in the era of targeted molecular therapy.ISRN Urol. 2014 Jan 23;2014:717295. doi: 10.1155/2014/717295. eCollection 2014. ISRN Urol. 2014. PMID: 24587921 Free PMC article. Review.
-
Role of surgery in advanced/metastatic renal cell carcinoma.Indian J Urol. 2010 Apr;26(2):167-76. doi: 10.4103/0970-1591.65381. Indian J Urol. 2010. PMID: 20877591 Free PMC article.
-
Molecular diagnosis and therapy of kidney cancer.Annu Rev Med. 2010;61:329-43. doi: 10.1146/annurev.med.042808.171650. Annu Rev Med. 2010. PMID: 20059341 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials